Navigation Links
Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

HAYWARD, Calif., April 10, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated announced data will be presented on the Company's clinical and preclinical pipeline, including its Hsp90 inhibitor, epothilone and nuclear export inhibitor programs, at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), being held in Los Angeles, April 14-18, 2007.

Poster presentations on Kosan's programs are as follows. The location for all poster presentations is the Los Angeles Convention Center Exhibit Hall.


    Date   Abstract #   Title             Session          Poster  Poster #

                                                           Section

    4/15

    1:00-  1544         Tanespimycin:     Experimental     32      4

    5:00                 No effects on     and Molecular

                         QTC interval      Therapeutics 13

                         using two

                         formulations


    4/15

    1:00-  1568         Preclinical       Experimental     32      28

    5:00                 safety profile    and Molecular

                         of tanespimycin   Therapeutics 13

                         (KOS-5: 953) --

                         a heat shock

                         protein 90

                         (Hsp90)

                         inhibitor


    4/15

    1:00-  1438         KOS-1803: A new,  Experimental     27      19

    5:00                 rationally        and Molecular

                         designed          Therapeutics 8

                         epothilone

                         analog with an

                         improved

                         pharmacological

                         profile and

                         efficacy in

                         xenograft mouse

                         models


    4/18

    8:00-  5597         Anti-tumor        Experimental     29      2

    12:00                activity of       and Molecu
'"/>




Page: 1 2 3 

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90
Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory
Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity
and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing
Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity
of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel
Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On
Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor
Tanespimycin (KOS-953) at AACR
8. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
9. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
Post Your Comments:
(Date:5/17/2013)... May 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ... that is developing new, patent-pending technologies poised to redefine how ... it will hold a business update teleconference and webcast for ... , 2013 at 4:30 PM ET. Fuse ... host the call and will be joined by ...
(Date:5/17/2013)... , May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... study, JAKARTA , examining the selective ... endpoint in both dose groups. The primary endpoint assessed ... volume. Consistent with data reported in previous trials, the ... vomiting. Full results will be presented at an upcoming ...
(Date:5/16/2013)... and ZURICH , May 17, 2013 /PRNewswire/ ... Science, Technology and Research (A*STAR) and Switzerland,s ... volunteer has been dosed in a Phase 1 clinical trial ... bacteriophage Qbeta virus-like particle (VLP) technology. In this first Phase ... vaccine candidate and its potential to protect against H1N1 influenza ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
... April 30 American Pacific Corporation ( APFC) ... quarter financial results on Thursday, May 6, 2010 , immediately after the ... Pacific Time . , , ... Executive Officer, invites you to participate in the teleconference to discuss ...
... , EAST BRUNSWICK, N.J. , April 30 Savient Pharmaceuticals, ... results for the first quarter 2010 following the close of the market on ... , , ... and Chief Financial Officer, will host an investment community conference call beginning at ...
Cached Medicine Technology:American Pacific to Release Financial Results and Hold Fiscal 2010 Second Quarter Investor Teleconference 2Savient Pharmaceuticals To Hold First Quarter 2010 Results 2
(Date:5/19/2013)... 19 (HealthDay News) -- Although spring arrived late this ... allergy season will still be strong, according to a ... Dr. Richard Waguespack, clinical professor in the university,s ... in a robust summer allergy season. However, some simple ... wheezing and coughing, he added. "Tree pollen has ...
(Date:5/19/2013)... 2013 Healthcare leaders will gather at ... the Walt Disney World Swan and Dolphin in Orlando, ... innovation, care delivery and healthcare reform and implementation. , ... healthcare markets, with consolidation, efficiency and reduced ... Todd Ebert, Amerinet president and CEO. “There is a ...
(Date:5/19/2013)... New York (PRWEB) May 19, 2013 ... in a federal litigation now underway in U.S. District ... Case Management Order dated May 3rd, the Court has ... Nominee Pool to eight cases rather than four. The ... scheduled for Thursday, May 23rd. (In re: Actos Product ...
(Date:5/19/2013)... 2013 According to a new ... Forecast (2013 – 2018): By Applications (Healthcare (Endoscopy, ... (CCD, CMOS, Contact IS, Infrared, X-Ray) And Geography" ... market was $8.00 billion in 2012 and is ... an estimated CAGR of 3.84% from 2013 to ...
(Date:5/19/2013)... Fat Burning Furnace developed by Rob Poulos ... with fat burning diet plans, training workouts, ... Furnace package, people will receive the Fat Burning Furnace ... The Fat Burning Furnace manual includes fat loss knowledge, ... mass. In addition, this book covers step-by-step instructions, techniques ...
Breaking Medicine News(10 mins):Health News:Managing Seasonal Allergies 2Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Fat Burning Diet | How “Fat Burning Furnace” Helps People Lose Their Weight Naturally And Fast – V-kool 2
... Erdogan tried to quell fears of a pandemic by saying ... country // , is now under control. ... monitor it closely," Erdogan newsmen with visiting Japanese Prime Minister ... out of the question," he added. People identified as carriers ...
... Indians (NRI) have been called upon by Oscar Fernandes, ... to take an active part in the AIDS awareness ... the involvement of related agencies and organizations to contribute ... announcement while addressing the Panel Discussion on HIV/AIDS in ...
... flu in the UK is reported to be on the decline. The ... 100,000 people. This figure // has been on the decline since ... for this is reported to be the immunity that the people in ... mutations it goes through every year. ,Most of the ...
... of Bonn in Germany have come up with what could be ... in sunflowers prevents // the AIDS virus from replicating in cell ... to the actual disease. ,The substance called as 'DCQA' ... AIDS drugs. But this is available in very minute quantities and ...
... a controversial procedure used to stitch up the torn hymen ... popularity in the United States // , for different reasons. ... - long considered the only positive proof of virginity - ... American Society of Plastic Surgeons says. ,Gynecologists ...
... to the transport you use. Travelling by taxis results ... least. // ,Research published in the ... College, London, and the Health and Safety Laboratory, Buxton, ... different modes of transport across London. ,Ultra ...
Cached Medicine News:Health News:Turkish PM says bird flu under control 2Health News:Sunflowers Could Hold the Key to New Class of AIDS Drugs 2Health News:A taxi could increase your exposure to pollution 2
These handy dispensers save space and organize gloves in labs and next to hand washers. Clear acrylic. Many other sizes and custom configurations available....
Single side double clamp knife holder for the Vibratome 8000...
... The Starter Package is ... up your laboratory. The package ... accessory kit, additional mounting blocks, ... head, and a rotating stage ...
... Package is a solid solution ... The package includes the Vibratome ... mounting blocks, v-block adapter, specimen ... rotating stage assembly for ease ...
Medicine Products: